174 results
8-K
EX-99.1
AXDX
Accelerate Diagnostics Inc
29 Mar 24
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
5:19pm
million and $2.0 million, respectively, for the same periods.
Research and development (R&D) costs for the quarter were $5.6 million, compared … -based compensation of $3.7 million and $8.5 million, respectively, for the same periods.
Research and development (R&D) costs were $25.4 million
8-K
EX-99.2
AXDX
Accelerate Diagnostics Inc
29 Mar 24
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
5:19pm
Research and development expenses were $5.6 million for the quarter and $25.4 million year-to-date. This compares to $6 million and $26.9 million
424B1
AXDX
Accelerate Diagnostics Inc
22 Jan 24
Prospectus with pricing info
9:59pm
current research and development areas of focus include the potential addition, if authorized by the FDA, of new AST content for our Accelerate Pheno system … , the primary focus of our current research and development efforts is our next generation AST platform, Wave, which is being developed with the goal to have
S-1/A
EX-1.1
90siwo0pkehg6f
16 Jan 24
IPO registration (amended)
7:18am
S-1/A
kv4fnwpewxcwlhjq8
16 Jan 24
IPO registration (amended)
7:18am
S-1
0l2r6lxza2itbztzzipf
13 Dec 23
IPO registration
5:30pm
8-K
vxhbyrk gf
13 Dec 23
December 2023 Company Presentation
5:05pm
8-K
EX-99.1
hq7fr2cgdk
9 Nov 23
Accelerate Diagnostics Reports Third Quarter 2023 Results
4:06pm
8-K
EX-99.1
qo3 t1l01rqos
10 Aug 23
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
v1l1xqjhg63ctofz58r
13 Jun 23
Entry into a Material Definitive Agreement
9:06am
SD
EX-1.01
jkkkd26i
31 May 23
Conflict minerals disclosure
4:10pm
8-K
EX-99.1
49ty 6bjbe
11 May 23
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
4:07pm